Company intelligence / Profile preview

The Nutmeg Group

New Haven, Connecticut, United States

Ownership: Private
Development stage: Other

Overview

Nutmeg Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation mRNA therapies for rare metabolic disorders. Founded by researchers from Yale University and the University of Connecticut, the company utilizes a proprietary platform designed to enhance the stability and delivery of mRNA molecules. Their lead programs target conditions such as phenylketonuria (PKU) by restoring the function of deficient enzymes like phenylalanine hydroxylase. Nutmeg Therapeutics aims to overcome current limitations in mRNA technology to provide more durable and effective treatments for patients with life-altering genetic diseases.

Therapeutic areas: Rare DiseasesMetabolic Disorders
Modalities: mRNA-based drugsSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on The Nutmeg Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Nutmeg Group.

Explore the full profile